{
    "id": "dbpedia_7110_0",
    "rank": 37,
    "data": {
        "url": "https://d18rn0p25nwr6d.cloudfront.net/CIK-0001764046/1ccbf8aa-701f-4474-bb23-bd64f7058c8e.html",
        "read_more_link": "",
        "language": "en",
        "title": "CLARIVATE PLC (Form: SC 13D",
        "top_image": "",
        "meta_img": "",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "CUSIP No. G21810109\n\nThis Amendment No. 4 (the Amendment No. 4) relates to the Schedule 13D filed on October 23, 2023 (the Original Schedule 13D) by (1) Giovanni Agnelli B.V. (G.A.), (2) Exor N.V. (Exor) and (3) Exor Nederland N.V. (Exor Nederland) and together with G.A. and Exor, the (Reporting Persons, and individually referred to herein as a Reporting Person), and amended by Amendment No. 1 to Schedule 13D filed on November 8, 2023, Amendment No. 2 to Schedule 13D filed on December 4, 2023 and Amendment No. 3 filed on December 19, 2023. Except as otherwise provided herein, each Item of the Original 13D, as amended, remains unchanged.\n\nItem 2. Identity and Background.\n\nItem 2 of the Original Schedule 13D, as amended, is hereby amended and restated in its entirety as follows.\n\nThe information set forth in Items 3, 4, 5 and 6 of this Schedule 13D, as amended, is incorporated by reference in its entirety into this Item 2.\n\n(a) Name of Person Filing\n\nThis Amendment No. 4 13D is being filed jointly by (1) Giovanni Agnelli B.V. (G.A.), (2) Exor N.V. (Exor) and (3) Exor Nederland N.V. (Exor Nederland) and together with G.A. and Exor, the (Reporting Persons, and individually referred to herein as a Reporting Person). The joint filing agreement of the Reporting Persons is attached as Exhibit 99.1 to the Original Schedule 13D.\n\nExor Nederland is a wholly-owned subsidiary of Exor, which in turn is controlled by G.A.\n\n(b) Address of Principal Business Office or, if none, Residence\n\nThe principal business office of the Reporting Persons is: c/o Exor N.V. Gustav Mahlerplein 25A, 1082 MS Amsterdam, The Netherlands.\n\n(c) Principal Business\n\nG.A. is a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) grouping the descendants of Senator Giovanni Agnelli, the founder of Fiat. The main business objective of G.A. is to preserve unity and continuity of the Agnelli familys controlling equity interest in Exor. The name, business address, present principal occupation or employment (and the name, principal business and address of any corporation or other organization in which such employment is conducted) and citizenship of each executive officer and director of G.A. each person controlling G.A. and each executive officer and director of any corporation or other person in control of G.A. are set forth in Schedule A attached hereto.\n\nExor and Exor Nederland are each Dutch public limited liability companies (naamloze vennootschap), and each is an investment company that focuses its business on long-term investments in global companies in diversified sectors, mainly in Europe and the United States. The name, business address, present principal occupation or employment (and the name, principal business and address of any corporation or other organization in which such employment is conducted) and citizenship of each executive officer and director of Exor and Exor Nederland, each person controlling Exor and Exor Nederland and each executive officer and director of any corporation or other person in control of Exor and Exor Nederland are set forth in Schedule A attached hereto.\n\n(d)-(e)\n\nDuring the last five years, none of the Reporting Persons have been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.\n\n(f) Citizenship\n\nGiovanni Agnelli B.V.  the Netherlands\n\nExor N.V.  the Netherlands\n\nExor Nederland N.V.  the Netherlands\n\nItem 3. Source and Amount of Funds or Other Consideration.\n\nItem 3 of the Original Schedule 13D, as amended, is hereby amended and supplemented by adding the following information:\n\nAll Shares purchased by the Reporting Persons were purchased using investment capital of the Reporting Persons.\n\nPage 5 of 13\n\nCUSIP No. G21810109\n\nItem 4. Purpose of Transaction.\n\nItem 4 of the Original Schedule 13D, as amended, is hereby amended and restated in its entirety as follows:\n\nThe information set forth in Items 3, 5 and 6 of this Schedule 13D, as amended, is incorporated by reference in its entirety into this Item 4.\n\nThe Reporting Persons have invested in the Issuer as part of a diversified portfolio of investments across a range of industries and in order to increase their exposure to the information analytics sector.\n\nOn March 4, 2024, Exor and Clarivate entered into an Investment Agreement, a copy of which is attached hereto as Exhibit 99.3 (the Investment Agreement). The key terms of the Investment Agreement are described in Item 6 of this Schedule 13D, as amended.\n\nExcept as described in this Schedule 13D, as amended, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Persons, may, at any time and from time to time, review, reconsider and change their position and/or change their purpose and/or develop such plans and, in connection therewith, may seek to influence management or the Board of Clarivate with respect to the business and affairs of Clarivate and may from time to time consider pursuing or proposing such matters with advisors, Clarivate or other persons.\n\nAccordingly, the Reporting Persons reserve the right to develop, modify or change their plans as they deem appropriate, subject to the restrictions in the Investment Agreement. In reaching any determination as to their future course of action, the Reporting Persons may take into consideration various factors, such as Clarivates business and prospects, other developments concerning Clarivate, other business opportunities available to the Reporting Persons, and general economic and stock market conditions, including, but not limited to, the trading prices of the Shares.\n\nSubject to the restrictions in the Investment Agreement, representatives of the Reporting Persons may from time to time participate in discussion with one another as well as with management of Clarivate, Clarivates directors, Clarivates other shareholders and/or other relevant parties, including other companies that operate in the information analytics sector or other markets in which Clarivate conducts its businesses, in each case relating to matters that may include Clarivates strategic plans, business, financial condition, operations and capital structure. Subject to the restrictions in the Investment Agreement, the Reporting Persons may engage with any of the parties listed above in discussions that may include one or more of the other actions described in subsections (a) through (j) of Item 4 of Schedule 13D. As a result of these activities, the Reporting Persons may suggest, or take a position with respect to, potential changes in the operations, management or capital structure of Clarivate as a means of enhancing shareholder value and the return on its investment in Clarivate. Such suggestions or positions may relate to one or more of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D under Rule 13d-1(a), including, without limitation, Clarivates business, results of operations, strategic direction and alternatives, management, board of directors and management composition, environmental, social and governance considerations, capital structure and capital and resource allocation.\n\nItem 5. Interest in Securities of the Issuer.\n\nItem 5(c) of the Original Schedule 13D, as amended, is hereby amended and supplemented by adding the following information.\n\n(c) The information set forth in Items 3 and 4 of this Schedule 13D, as amended, is incorporated by reference herein. Exhibit 99.2, which is incorporated by reference into this Item 5(c) as if restated in full, describes all of the transactions in the class of securities reported in this Schedule 13D (as amended) that were effected by the Reporting Persons in the past 60 days. Except as set forth in Exhibit 99.2 attached hereto, no reportable transactions were effected by any Reporting Person within the last 60 days.\n\n(d) Neither the Reporting Persons nor, to the knowledge of the Reporting Persons, any of the persons listed on Schedule A, which is incorporated by reference hereto, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the securities indicated in this Item 5.\n\nItem 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.\n\nItem 6 of the Original Schedule 13D, as amended, is hereby amended and supplemented by adding the following information:\n\nOn March 4, 2024, Exor and the Issuer entered into the Investment Agreement, a copy of which is attached hereto as Exhibit 99.3. Under the terms of the Investment Agreement, the Issuer has agreed to include in the Issuers board of directors slate of nominees, for election as director at the Issuers 2024 annual meeting of shareholders, Suzanne Heywood, Exors Chief Operating Officer, or, if Ms. Heywood becomes unavailable to serve as director, another individual designated by Exor and reasonably acceptable to the Issuers board of directors (the Exor Designee). The Exor Designee will be required to promptly tender his or her resignation from the Issuers board of directors at such time at which Exor beneficially owns less than 5% of the issued and outstanding Shares.\n\nPage 6 of 13"
    }
}